<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03570138</url>
  </required_header>
  <id_info>
    <org_study_id>SPIDER-STYLE</org_study_id>
    <nct_id>NCT03570138</nct_id>
  </id_info>
  <brief_title>Efficacy of Flash Glucose-Sensing Technology on the Occurrence of Cardiac Arrhythmias Associated With Hypoglycemia</brief_title>
  <official_title>Efficacy of Flash Continuous Glucose Monitoring (FREESTYLE LIBRE) on the Occurrence of Cardiac Arrhythmias Associated With Hypoglycemia in Patients With Type 2 Diabetes, High Risk of Hypoglycemia and Insulin Therapy : Open-label Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoglycemia, frequently asymptomatic, may lead to cardiac arrythmias and induce an increased&#xD;
      risk of cardiovascular morbidity and mortality in patients with type 2 diabetes (T2D). The&#xD;
      study hypothesize is that the hypoglycemia reduction, achieved with the FREESTYLE LIBRE&#xD;
      device, a Glucose Continuous Monitoring system, may decrease cardiac arrythmias associated&#xD;
      with hypoglycemia. So the main objective is to evaluate the efficacy of the FREESTYLE LIBRE&#xD;
      system, associated with a specific therapeutic education on the cardiac arrythmias reduction,&#xD;
      compared to a capillary ASG system with standard therapeutic education, in patient with T2D&#xD;
      with high risk of hypoglycemia.&#xD;
&#xD;
      This is a open, multicenter, controlled, randomized study in parallel group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of cardiac arrythmic events during a 14 days Continuous ECG Monitoring</measure>
    <time_frame>14 days</time_frame>
    <description>Cardiac arrythmic events :&#xD;
Bradycardia &lt; 45 bpm for ≥ 10 seconds&#xD;
or Asystole ≥ 3 seconds&#xD;
or Atrial Fibrillation ≥ 30 seconds&#xD;
or Non-sustained ventricular tachycardia defined as runs of beats arising from the ventricles with duration between 3 beats and 30 s with QRS ≥ 120ms and with RR intervall ≤ 600 ms (&gt;100 bpm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of each component of the primary outcome</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of ≥ 5 minutes Atrial Fibrillation episodes</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean QT interval</measure>
    <time_frame>First 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of ventricular extrasystoles</measure>
    <time_frame>First 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Insulin Treated Type 2 Diabetes With High Risk of Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Flash continuous glucose monitoring system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will wear the FREESTYLE LIBRE device and receive a specific therapeutic education for its use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard self monitoring blood glucose system</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will use their own usual self monitoring blood glucose system and receive a C They will wear a masked FREESTYLE LIBRE Pro system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System</intervention_name>
    <description>Specific therapeutic education for diabetes self management</description>
    <arm_group_label>Flash continuous glucose monitoring system</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Usual self monitoring Blood Glucose device</intervention_name>
    <description>Standard therapeutic education for diabetes self management</description>
    <arm_group_label>Standard self monitoring blood glucose system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Type 2 diabetes (diagnosis based on the World Health Organization criteria)&#xD;
&#xD;
          -  Treatment with insulin therapy (continuous subcutaneous insulin Infusion or more than&#xD;
             1 daily injection)&#xD;
&#xD;
          -  Resting heart beat ≥ 60bpm&#xD;
&#xD;
          -  High risk of hypoglycemia defined as :&#xD;
&#xD;
               -  Estimated glomerular filtration rate 15-59 ml/min/1.73 m² (according to CKD-EPI&#xD;
                  formula)&#xD;
&#xD;
               -  Or history of stable proliferative diabetic retinopathy&#xD;
&#xD;
               -  Or body mass index ≤ 30 kg/m²&#xD;
&#xD;
               -  Or history of severe hypoglycemia in the previous 6 months&#xD;
&#xD;
               -  Or history of non-severe ≤70mg/dL hypoglycemia in the previous 4 weeks&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus or diabetes due to other cause&#xD;
&#xD;
          -  History of atrial fibrillation&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt;15 ml/min/1.73 m² (according to CKD-EPI formula)&#xD;
&#xD;
          -  Currently using a flash continuous Glucose Monitoring device&#xD;
&#xD;
          -  In the investigator's opinion, acute or chronic medical condition considered as&#xD;
             unsuitable for inclusion in the study .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>SAULNIER Pierre-Jean, Prof.</last_name>
    <phone>+33 549444689</phone>
    <email>pierre-jean.saulnier@chu-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BONNIN Marie, Project chief</last_name>
    <phone>+33 549443317</phone>
    <email>Marie.BONNIN@chu-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital, Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MOHAMMEDI Kamel, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital, Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>TEISSIER Marie-Pierre, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital, Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>CARIOU Bertrand, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital, Niort</name>
      <address>
        <city>Niort</city>
        <zip>79000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>TEYNIE Julie, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital, Pau</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>TEYNIE Julie, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital, Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>SAULNIER Pierre-Jean, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital, Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>GOURDY Pierre, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Freestyle libre</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Hypoglycemia-induced cardiac arrhythmias</keyword>
  <keyword>Flash Continuous Glucose Monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

